AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2572616 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine hydrochloride, 8.8 mg
Number of subjects: 12
Study 2572616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 827393 — intervention group
Group type: EXPERIMENTAL
Intervention: Pollinex (glutaraldehyde‐pollen‐tyrosine adsorbate)
Number of subjects: 112
Study 827393 — intervention group
Group type: COMPARATOR
Intervention: Alavac-P (alum‐precipitated pyridine extract)
Number of subjects: 112
Study 827393 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 112
Study 29098501 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous carperitide (0.02 μg/kg/min) in addition to standard treatment
Number of subjects: 260
Study 29098501 — intervention group
Group type: COMPARATOR
Intervention: Matching standard treatment
Number of subjects: 260
Study 25336731 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural A(H1N1)pdm09 infection
Number of subjects: 0
Study 25336731 — intervention group
Group type: COMPARATOR
Intervention: Inactivated A(H1N1)pdm09 vaccine
Number of subjects: 0
Study 24409779 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified apocrine gland removal surgery with high radiofrequency knife (Group B)
Number of subjects: 105
Study 24409779 — intervention group
Group type: COMPARATOR
Intervention: Traditional apocrine gland removal surgery (Group A)
Number of subjects: 105
Study 21682864 — intervention group
Group type: EXPERIMENTAL
Intervention: COPE-ICD programme (1-year psycho-educational component + 12-week exercise training)
Number of subjects: 196
Study 21682864 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 196
Study 19549426 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine 0.6% nasal spray (2 sprays/nostril b.i.d.)
Number of subjects: 130
Study 19549426 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate 50 microg nasal spray (2 sprays/nostril q.d.)
Number of subjects: 130
Study 19549426 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine 0.6% nasal spray
Number of subjects: 130
Study 19549426 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine 0.6% nasal spray and Fluticasone propionate 50 microg nasal spray
Number of subjects: 130
Study 19549426 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate 50 microg nasal spray
Number of subjects: 130
Study 16432345 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted surgery
Number of subjects: 60
Study 16432345 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 60
Study 16432345 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 14530982 — intervention group
Group type: EXPERIMENTAL
Intervention: Power training (twice a week for 15 weeks)
Number of subjects: 23
Study 14530982 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 23
Study 11412248 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted colectomy
Number of subjects: 236
Study 11412248 — intervention group
Group type: COMPARATOR
Intervention: Conventional open surgery
Number of subjects: 236
Study 9401885 — intervention group
Group type: EXPERIMENTAL
Intervention: nDTPw
Number of subjects: 812
Study 9401885 — intervention group
Group type: COMPARATOR
Intervention: Triple Antigen
Number of subjects: 812
Study 8216567 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen sodium 550 mg twice daily for 10 days
Number of subjects: 120
Study 8216567 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 120
Study 31977324 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal strength training
Number of subjects: 54
Study 31977324 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 54
Study 29483043 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg/d)
Number of subjects: 0
Study 27936233 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir (LPV-rtv) based ART with anti-malarial treatment
Number of subjects: 31
Study 27936233 — intervention group
Group type: COMPARATOR
Intervention: Nevirapine (NVP) based ART
Number of subjects: 31
Study 25429720 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.15 μg(‐1)kgIBW(‐1) min(‐1))
Number of subjects: 126
Study 25429720 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (200 to 500 μg as needed)
Number of subjects: 126
Study 23236595 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex psycho-social intervention program
Number of subjects: 173
Study 20490354 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment for 4 weeks
Number of subjects: 43
Study 18577583 — intervention group
Group type: EXPERIMENTAL
Intervention: Asics Nimbus 6
Number of subjects: 22
Study 18577583 — intervention group
Group type: EXPERIMENTAL
Intervention: Brooks Glycerin 3
Number of subjects: 22
Study 18577583 — intervention group
Group type: COMPARATOR
Intervention: Control (Dunlop Volley)
Number of subjects: 22
Study 18577583 — intervention group
Group type: EXPERIMENTAL
Intervention: Both neutral-cushioned running shoes
Number of subjects: 22
Study 16448296 — intervention group
Group type: EXPERIMENTAL
Intervention: Sun-protection program
Number of subjects: 211
Study 16448296 — intervention group
Group type: COMPARATOR
Intervention: Stress management (control) program
Number of subjects: 211
Study 12811362 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (250 mL)
Number of subjects: 4
Study 12811362 — intervention group
Group type: EXPERIMENTAL
Intervention: Lime juice (one quarter-strength)
Number of subjects: 4
Study 12811362 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine
Number of subjects: 4
Study 12811362 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 4
Study 11225745 — intervention group
Group type: EXPERIMENTAL
Intervention: SIMP (Simplified)
Number of subjects: 15
Study 11225745 — intervention group
Group type: EXPERIMENTAL
Intervention: QUAL (Qualitative)
Number of subjects: 15
Study 11225745 — intervention group
Group type: EXPERIMENTAL
Intervention: QUANT (Quantitative)
Number of subjects: 15
Study 11225745 — intervention group
Group type: COMPARATOR
Intervention: All strategies
Number of subjects: 15
Study 11225745 — intervention group
Group type: EXPERIMENTAL
Intervention: SIMP to QUANT
Number of subjects: 15
Study 9573887 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary expansion and protraction facemask
Number of subjects: 20
Study 8472828 — intervention group
Group type: EXPERIMENTAL
Intervention: (+/‐)‐telenzepine (3 mg orally at 6 p.m. for 5 days)
Number of subjects: 21
Study 8472828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 3513692 — intervention group
Group type: EXPERIMENTAL
Intervention: Local radiotherapy (45 Gy)
Number of subjects: 0
Study 3513692 — intervention group
Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 0
Study 30807234 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus fulvestrant
Number of subjects: 521
Study 30807234 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus fulvestrant
Number of subjects: 521
Study 30807234 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib in the POP trial
Number of subjects: 521
Study 30393030 — intervention group
Group type: EXPERIMENTAL
Intervention: One to one intervention by a nurse including education and exercise training prior to surgery
Number of subjects: 60
Study 27385377 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Foley's catheter and vaginal misoprostol
Number of subjects: 210
Study 27385377 — intervention group
Group type: COMPARATOR
Intervention: Foley's catheter or low-dose vaginal misoprostol alone
Number of subjects: 210
Study 24932625 — intervention group
Group type: EXPERIMENTAL
Intervention: intralymphatic immunotherapy (ILIT)
Number of subjects: 112
Study 24932625 — intervention group
Group type: COMPARATOR
Intervention: subcutaneous immunotherapy (SCIT)
Number of subjects: 112
Study 23075021 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 0
Study 23075021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20927344 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized Controlled Trials (RCTs)
Number of subjects: 578
Study 20927344 — intervention group
Group type: COMPARATOR
Intervention: Controlled Clinical Trials (CCTs)
Number of subjects: 578
Study 20927344 — intervention group
Group type: EXPERIMENTAL
Intervention: Methodological quality (Jadad score)
Number of subjects: 578
Study 20927344 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind studies
Number of subjects: 578
Study 20927344 — intervention group
Group type: EXPERIMENTAL
Intervention: Studies with adequate allocation concealment
Number of subjects: 578
Study 20927344 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting of withdrawals and losses to follow-up
Number of subjects: 578
Study 20927344 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample size calculations
Number of subjects: 578
Study 20927344 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention-to-treat analysis
Number of subjects: 578
Study 20927344 — intervention group
Group type: EXPERIMENTAL
Intervention: Industry funding
Number of subjects: 578
Study 20927344 — intervention group
Group type: COMPARATOR
Intervention: Positive conclusions from industry-funded studies
Number of subjects: 578
Study 17652881 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of non-expanded peripheral blood mononuclear cells (PBMNCs) within 5 days after PCI
Number of subjects: 0
Study 17652881 — intervention group
Group type: COMPARATOR
Intervention: Standard PCI for similar AMI (Control group)
Number of subjects: 0
Study 17652881 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of PBMNCs
Number of subjects: 0
Study 15704689 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil, a phosphodiesterase 5 inhibitor; dosage and duration not specified.
Number of subjects: 0
Study 15704689 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified; no specific control intervention mentioned.
Number of subjects: 0
Study 12015188 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg (titrated to 80 mg after 4 weeks)
Number of subjects: 252
Study 12015188 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10 mg (titrated to 20 mg after 4 weeks)
Number of subjects: 252
Study 12015188 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg / Enalapril 10 mg
Number of subjects: 252
Study 10369630 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate-day omeprazole therapy
Number of subjects: 0
Study 10369630 — intervention group
Group type: EXPERIMENTAL
Intervention: On-demand therapy with omeprazole
Number of subjects: 0
Study 7594361 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Mental Status Examination (BMSE)
Number of subjects: 100
Study 7594361 — intervention group
Group type: EXPERIMENTAL
Intervention: Ease of administration of BMSE
Number of subjects: 100
Study 2267903 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterialization (ART)
Number of subjects: 64
Study 389354 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole (local treatment for 6 days)
Number of subjects: 100
Study 389354 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole (local treatment for 6 days) + Nystatin (oral treatment for 10 days)
Number of subjects: 100
Study 30922282 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching plus education (9, 20-min telephone-based sessions with a certified coach and 6 webinar-based education sessions focused on physical activity and nutrition)
Number of subjects: 50
Study 30922282 — intervention group
Group type: COMPARATOR
Intervention: Education only (6 webinar-based education sessions focused on physical activity and nutrition)
Number of subjects: 50
Study 28936905 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave diathermy (MWD) and transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 88
Study 28936905 — intervention group
Group type: COMPARATOR
Intervention: Microwave diathermy (MWD) and placebo TENS
Number of subjects: 88
Study 28936905 — intervention group
Group type: COMPARATOR
Intervention: Placebo MWD and TENS
Number of subjects: 88
Study 28936905 — intervention group
Group type: COMPARATOR
Intervention: Placebo MWD and placebo TENS
Number of subjects: 88
Study 28936905 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 88
Study 25801708 — intervention group
Group type: EXPERIMENTAL
Intervention: EADB-100 (Quadruple therapy with esomeprazole, amoxicillin, DOX-100 mg b.i.d., and bismuth subcitrate)
Number of subjects: 103
Study 25801708 — intervention group
Group type: EXPERIMENTAL
Intervention: EADB-200 (Quadruple therapy with esomeprazole, amoxicillin, DOX-200 mg b.i.d., and bismuth subcitrate)
Number of subjects: 103
Study 23600548 — intervention group
Group type: EXPERIMENTAL
Intervention: 300IR 5-grass pollen sublingual tablet (4M group)
Number of subjects: 435
Study 23600548 — intervention group
Group type: EXPERIMENTAL
Intervention: 300IR 5-grass pollen sublingual tablet (2M group)
Number of subjects: 435
Study 23600548 — intervention group
Group type: EXPERIMENTAL
Intervention: 300IR 5-grass pollen sublingual tablet
Number of subjects: 435
Study 23600548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 435
Study 22193793 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led intervention (In Our Own Voice-Family Companion [IOOV-FC])
Number of subjects: 158
Study 22193793 — intervention group
Group type: COMPARATOR
Intervention: Clinician-led family education session
Number of subjects: 158
Study 19125990 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg
Number of subjects: 191
Study 19125990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study 17235042 — intervention group
Group type: EXPERIMENTAL
Intervention: BEP + HDCT
Number of subjects: 219
Study 17235042 — intervention group
Group type: COMPARATOR
Intervention: BEP alone
Number of subjects: 219
Study 17235042 — intervention group
Group type: EXPERIMENTAL
Intervention: BEP + HDCT (among patients with unsatisfactory marker decline)
Number of subjects: 219
Study 17235042 — intervention group
Group type: COMPARATOR
Intervention: BEP alone (among patients with unsatisfactory marker decline)
Number of subjects: 219
Study 17235042 — intervention group
Group type: EXPERIMENTAL
Intervention: BEP + HDCT and BEP alone (regarding serum tumor marker decline)
Number of subjects: 219
Study 12641501 — intervention group
Group type: COMPARATOR
Intervention: Conventional 13C-UBT (75 mg 13C-urea)
Number of subjects: 200
Study 12641501 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based 13C-UBT (100 mg 13C-urea)
Number of subjects: 200
Study 12641501 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based 13C-UBT (50 mg 13C-urea)
Number of subjects: 200
Study 12641501 — intervention group
Group type: COMPARATOR
Intervention: Conventional 13C-UBT (75 mg 13C-urea) at follow-up
Number of subjects: 200
Study 12641501 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based 13C-UBT (100 mg 13C-urea) at follow-up
Number of subjects: 200
Study 12641501 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based 13C-UBT (50 mg 13C-urea) at follow-up
Number of subjects: 200
Study 10704542 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracapsular cataract extraction and posterior chamber lens implantation with trabeculectomy
Number of subjects: 35
Study 10704542 — intervention group
Group type: COMPARATOR
Intervention: Extracapsular cataract extraction and posterior chamber lens implantation without trabeculectomy
Number of subjects: 35
Study 9350364 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine (Group NAL)
Number of subjects: 80
Study 9350364 — intervention group
Group type: COMPARATOR
Intervention: Diphenhydramine (Group DIP)
Number of subjects: 80
Study 8478759 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.35 mg/kg)
Number of subjects: 0
Study 8478759 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (0.70 mg/kg)
Number of subjects: 0
Study 8478759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3094356 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release nitroglycerin, 13 mg
Number of subjects: 15
Study 3094356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3094356 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem, 60 mg
Number of subjects: 15
Study 3094356 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nitroglycerin and diltiazem
Number of subjects: 15
Study 31700615 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1 receptor antagonist (IL-1Ra)
Number of subjects: 0
Study 31700615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31700615 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1Ra
Number of subjects: 0
Study 29109316 — intervention group
Group type: EXPERIMENTAL
Intervention: Formocresol (FC)
Number of subjects: 40
Study 29109316 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite (NaOCl)
Number of subjects: 40
Study 26333841 — intervention group
Group type: EXPERIMENTAL
Intervention: Currently available interventions for first-episode schizophrenia; specific interventions not detailed.
Number of subjects: 0
Study 23335852 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (CaD) 500 mg daily for 3 months
Number of subjects: 90
Study 23335852 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 90
Study 20358358 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg IV zoledronic acid
Number of subjects: 14
Study 20358358 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (control)
Number of subjects: 14
Study 19118117 — intervention group
Group type: EXPERIMENTAL
Intervention: S. aureus bacteremia
Number of subjects: 3359
Study 19118117 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-bloodstream S. aureus infections
Number of subjects: 3359
Study 16636210 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran, 36 mg twice daily
Number of subjects: 7329
Study 16636210 — intervention group
Group type: COMPARATOR
Intervention: Warfarin sodium (target international normalized ratio, 2.0‐3.0)
Number of subjects: 7329
Study 15646216 — intervention group
Group type: EXPERIMENTAL
Intervention: 18% carbamide peroxide (Group 1)
Number of subjects: 95
Study 15646216 — intervention group
Group type: EXPERIMENTAL
Intervention: 16.4% carbamide peroxide (Group 2)
Number of subjects: 95
Study 15646216 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 95
Study 11226087 — intervention group
Group type: EXPERIMENTAL
Intervention: RSR13 (75 mg/kg and 100 mg/kg doses)
Number of subjects: 26
Study 11226087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 11226087 — intervention group
Group type: EXPERIMENTAL
Intervention: RSR13 (all doses)
Number of subjects: 26
Study 10193229 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction applied under sterile drapes to avoid rebreathing of CO2 (Group B)
Number of subjects: 0
Study 10193229 — intervention group
Group type: COMPARATOR
Intervention: No air suction used (Group A)
Number of subjects: 0
Study 7845278 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine plus 100 micrograms fentanyl
Number of subjects: 31
Study 7845278 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine plain
Number of subjects: 31
Study 7845278 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine plus 50 micrograms fentanyl
Number of subjects: 31
Study 3258222 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (10 ml/kg; n = 15) using hydroxyethyl starch solution (HES)
Number of subjects: 30
Study 3258222 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated; n = 15)
Number of subjects: 30
Study 3258222 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups after ECC
Number of subjects: 30
Study 3258222 — intervention group
Group type: EXPERIMENTAL
Intervention: HD group
Number of subjects: 30
Study 3258222 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 29471711 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference-setting model for return of results regarding their child
Number of subjects: 0
Study 29471711 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrower set of IRRs preference
Number of subjects: 0
Study 28320482 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure relieving mattress (specific type not mentioned)
Number of subjects: 0
Study 28320482 — intervention group
Group type: EXPERIMENTAL
Intervention: Photographic assessment of skin sites
Number of subjects: 0
Study 28320482 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised camera and photographic technique
Number of subjects: 0
Study 25778112 — intervention group
Group type: EXPERIMENTAL
Intervention: Vastus Medialis Muscle %Fat increase of 1%
Number of subjects: 143
Study 25778112 — intervention group
Group type: EXPERIMENTAL
Intervention: Vastus Medialis Muscle area decrease of 1%
Number of subjects: 143
Study 25778112 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent presence of low VM area, high VM %Fat, and high BMI
Number of subjects: 143
Study 23177418 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-dose group (75 IU rHLH given as four equally divided doses)
Number of subjects: 27
Study 23177418 — intervention group
Group type: COMPARATOR
Intervention: Single-dose group (75 IU rHLH given as a single dose)
Number of subjects: 27
Study 23177418 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-dose group
Number of subjects: 27
Study 23177418 — intervention group
Group type: COMPARATOR
Intervention: Single-dose group
Number of subjects: 27
Study 21653935 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural intervention (motivational interviewing, provision of condoms, gloves, and water-based lubricant)
Number of subjects: 89
Study 21653935 — intervention group
Group type: COMPARATOR
Intervention: Control (general STI education)
Number of subjects: 89
Study 21653935 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural intervention
Number of subjects: 89
Study 21653935 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 89
Study 19657112 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma levels of sex hormone-binding globulin (SHBG)
Number of subjects: 529